Pacific Biosciences of Californ Price Today
Pacific Biosciences of Californ
PACB
Healthcare
$3.04B
💰
Market Cap
0
💸
Price to Earnings
$-1.4
🎉
EPS
+0
🌳
ESG
Consensus Recommendations
Buy Consensus
Buy |
8 |
Strong Buy |
4 |
Hold |
6 |
Sell |
0 |
Strong Sell |
0 |
PACB Price Forecast Target
12.2 👉 20.0 +64%
PACB EPS Forecast
-1.4 👉 -1.0 +-29%
Financials
Profit Margin
-218 %
Revenue Growth
34.1 %
Dividend
$ 0
Held Percent
1.7% - Insiders
97.0% - Institutions
1.3% - Public
Major Fund Holders
-
💰 ARK Investment Management, LLC $354.2M
-
💰 Vanguard Group Inc $258.0M
-
💰 Blackrock Inc. $233.9M
-
💰 Madrone Advisors, LLC $190.1M
-
💰 Nikko Asset Management Americas, Inc. $162.2M
Stock Ideas
Nelson Peltz Portfolio
Nelson Peltz is a renowned investor known for his astute investment strategies and activist approach. With a portfolio spanning diverse industries, Peltz strategically targets underperforming companies, advocating for changes that unlock their full …
Nancy Pelosi Portfolio
Nancy Pelosi is the Speaker of the United States House of Representatives and a savvy investor. Her personal portfolio is heavily weighted towards large-cap tech stocks, such as Apple and Microsoft. She also owns shares in several consumer staples a…
Stephen Mandel Portfolio
Stephen Mandel is the founder and portfolio manager of Lone Pine Capital, one of the largest and most successful hedge funds. Employing rigorous fundamental analysis, Mandel searches globally for qualitatively excellent growth companies trading at r…
David Tepper Portfolio
David Tepper is a renowned billionaire investor, widely known for his incredible success during the 2009 financial crisis where he made a staggering $4 billion. His financial prowess has earned him the distinction of being the 258th richest individ…📮FAQ
Some Frequently Asked Questions.
The Pacific Biosciences of Californ industry is Medical Devices
The Pacific Biosciences of Californ sector is Healthcare
The Pacific Biosciences of Californ forecasted predicted Price to Earnings PE ratio is -12.1
The Pacific Biosciences of Californ Price to Earnings PE ratio is 0
The Market Capitalization of Pacific Biosciences of Californ is $3.04B
There are total of 249909347 float shares with 97.0% held by Institutions and 1.7% held by insiders
The MPacific Biosciences of Californ forecasted Earnings per Share EPS is $-1.0
The Pacific Biosciences of Californ Earnings per Share EPS is -1.4
The Pacific Biosciences of Californ company has $53473000 gross profits with -218 profit margins
The Pacific Biosciences of Californ Earnings Growth is 0% with 0% quarterly earnings growth
The Pacific Biosciences of Californ Revenue is $146136992 with 0.341 revenue growth
The price target for Pacific Biosciences of Californ stock is $20.0 for the high target and $12.0 for the low target
The consensus analyst recommendations for Pacific Biosciences of Californ is Buy, however the decision to buy or sell the stock should be entirely yours, as you are earning your own money and hence responsible on how to allocate and spend them.
The consensus analyst recommendations for Pacific Biosciences of Californ is Buy, with the following breakdown:
- Buy: 8
- Strong Buy: 4
- Hold: 6
- Sell: 0
- Strong Sell: 0
The Beta of Pacific Biosciences of Californ is 1.6
The dividend of Pacific Biosciences of Californ is $0
The dividend yield of Pacific Biosciences of Californ is 0%
The biggest institutional and mutual fund holders of Pacific Biosciences of Californ stock are
- ARK Investment Management, LLC
- Vanguard Group Inc
- Blackrock Inc.
- Madrone Advisors, LLC
The Pacific Biosciences of Californ ESG Score is 0, with the following breakdown:
- E: 0
- S: 0
- G: 0